Targeting Inflammatory and Oncogenic Pathways: Cyclooxygenase-2, Epidermal Growth Factor Receptor, and p38...

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Organic Synthesis

Background:

• Inflammation is a key factor in numerous diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions.
• Cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2, are primary targets for anti-inflammatory drugs.
• COX enzymes are involved in prostaglandin synthesis and play roles in inflammation, cancer, and drug resistance.

Purpose of the Study:

• To synthesize novel pyrazolone derivatives with potential anti-inflammatory and anticancer activities.
• To evaluate the inhibitory effects of these compounds on cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzymes.
• To assess the anticancer potential and mechanism of action of the most active compounds.

Main Methods:

• Synthesis of eight pyrazolone derivatives.
• Structural characterization using NMR, IR, and HRMS spectroscopy.
• In vitro evaluation of COX-1, COX-2, and 5-LOX inhibitory activities.
• Assays for epidermal growth factor receptor (EGFR) and p38 mitogen-activated protein kinase (MAPK) inhibition.
• Selective cytotoxicity assays against cancer cell lines.

Main Results:

• Compounds 7 and 8 demonstrated selective inhibition of COX-2 over COX-1.
• Several synthesized derivatives exhibited selective cytotoxicity against cancer cell lines.
• Compound 7 showed potent COX-2 inhibition and was further investigated for kinase inhibition.
• Some cytotoxic compounds were not the most potent COX-2 inhibitors, suggesting diverse mechanisms.

Conclusions:

• The synthesized pyrazolone derivatives show promise as lead compounds for developing novel anti-inflammatory and anticancer therapeutics.
• Selective COX-2 inhibition and cytotoxic effects highlight their potential in treating inflammatory diseases and cancer.
• Further research is warranted to explore the full therapeutic potential and optimize these pyrazolone derivatives.